Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$ALT Q4 '24 Earnings Results & Recap Altimmune's Q4'24 results showed EPS of -$0.33 (matching expectations), with no reported revenue as expected. The upcoming Phase 2b readout for pamidutide in NASH and the initiation of Phase 2 trials for two additional indications are key catalysts for 2025, with potential for significant revenue generation if successful.
8
15

Since Post

Full Details
Top Replies
Master6
Looks like an AI generated post from the voice recording of the conf call.
3
1
NappyDadDude
Grasping for straws with Bearish highlights.
1
10
Edge
PashaGainz
also false on "uncertain data readouts"... 100% false as can was clearly indicated by the ALT leadership team. Q2 readout for MASH data on schedule. In two weeks PR for both of the 2 new INDs
1
6
Mateo2022
how is the data readouts uncertain when they said they'd announce them on the 13th?
1
1
Edge
PashaGainz
it’s Pemvidutide… missed a lot more major highlights but sure
8
NeverSellsAtTheRightTime
"pamidutide" lmao.
4
Edge
PashaGainz
also really low intellect to post about net loss on a clinical stage company with no revenue lmao who writes this nonsense... please hire an actual analyst's vs your call center buddies in Kolkata
3
Mikeiavelli
Yeah, AI is retarded How are the bearish comments actually bearish 😂
4

Advertisement|Remove ads.